Bone Biologics Corp WT BBLGW

$10.95 +0.10 (0.92%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$-4,110,000
PE ratio
—
Forward PE
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
600
Avg volume
1,408
Day's range
$10.90 – $10.95
Shares out
—
Stochastic %K
37%
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine impla...

Show more

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Phone
781 552 4452
Website
https://www.bonebiologics.com
Address
2 Burlington Woods Drive, Suite 100, Burlington, United States

Latest news

No headlines yet.